This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data
Learn about funding and reimbursement for England, Scotland, Wales and Northern Ireland
Scroll through our resources about acromegaly management, patient resources, and experience with acromegaly
Menu
Close
Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data
Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Percentage of Somavert patients achieving IGF-I normalisation after 12 weeks of treatment2
Study design: 12-week, randomised, double-blind study of three different doses of pegvisomant (10mg, 15mg, and 20mg) and placebo, given subcutaneously daily, in 112 patients with acromegaly. All patients had previously been treated with surgery, radiation therapy and/or medical therapies.2
A loading dose of 80mg Somavert should be administered subcutaneously under medical supervision. Following this, 10mg Somavert should be administered once daily as a sub-cutaneous injection.
Dose adjustments should be based on serum IGF-I levels. Serum IGF-I concentrations should be measured every four to six weeks and appropriate dose adjustments made in increments of 5 mg/day in order to maintain the serum IGF-I concentration within the age-adjusted normal range and to maintain an optimal therapeutic response.1
The dose range of Somavert is 10-30mg daily. The maximum dose should not exceed 30mg/day.1
†Please refer to the Summary of Product Characteristics for the full information regarding storage
We offer a range of services that help your patients at home with medication delivery and face-to-face support
Discover IGF-I normalisation rates with Somavert
To find out more about Somavert dosing, supporting your patients or to order starter kits
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024